AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20540639 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (LP: 0.6‐0.8 g/kg IBW/d, n = 13)
Number of subjects: 39
Study 20540639 — intervention group
Group type: COMPARATOR
Intervention: High protein diet (HP: 1.0‐1.2 g/kg IBW/d, n = 14)
Number of subjects: 39
Study 18988153 — intervention group
Group type: EXPERIMENTAL
Intervention: Mersilene mesh (Group A)
Number of subjects: 31
Study 18988153 — intervention group
Group type: COMPARATOR
Intervention: Autogenous fascia lata (Group B)
Number of subjects: 31
Study 16673835 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy plus education intervention
Number of subjects: 59
Study 16673835 — intervention group
Group type: COMPARATOR
Intervention: Education-only intervention
Number of subjects: 59
Study 12722741 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In labelling (0.74 MBq)
Number of subjects: 12
Study 12722741 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐HMPAO labelling (18.5 MBq)
Number of subjects: 12
Study 12722741 — intervention group
Group type: COMPARATOR
Intervention: Control group (DCs not incubated with MPL)
Number of subjects: 12
Study 12722741 — intervention group
Group type: EXPERIMENTAL
Intervention: MPL+ subgroup (both groups)
Number of subjects: 12
Study 10569461 — intervention group
Group type: EXPERIMENTAL
Intervention: Active filter
Number of subjects: 42
Study 10569461 — intervention group
Group type: COMPARATOR
Intervention: Inactive filter
Number of subjects: 42
Study 10569461 — intervention group
Group type: COMPARATOR
Intervention: No filter
Number of subjects: 42
Study 8678510 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) with leucovorin (LV)
Number of subjects: 0
Study 8678510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus i.v. infusion of 5‐FU
Number of subjects: 0
Study 8678510 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted i.v. infusion of 5‐FU
Number of subjects: 0
Study 8678510 — intervention group
Group type: EXPERIMENTAL
Intervention: New camptothecin derivative CPT‐11
Number of subjects: 0
Study 8678510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomudex (pure TS inhibitor)
Number of subjects: 0
Study 8678510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low‐dose cisplatin and 5‐FU
Number of subjects: 0
Study 8678510 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy
Number of subjects: 0
Study 8678510 — intervention group
Group type: EXPERIMENTAL
Intervention: New dihydropyrimidine dehydrogenase inhibitors
Number of subjects: 0
Study 8678510 — intervention group
Group type: EXPERIMENTAL
Intervention: New TS inhibitors
Number of subjects: 0
Study 1905621 — intervention group
Group type: EXPERIMENTAL
Intervention: ponalrestat 600 mg once daily for 6 weeks
Number of subjects: 21
Study 1905621 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 6754120 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of isoniazid
Number of subjects: 28000
Study 6754120 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of isoniazid
Number of subjects: 28000
Study 6754120 — intervention group
Group type: EXPERIMENTAL
Intervention: 52 weeks of isoniazid
Number of subjects: 28000
Study 6754120 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28000
Study 31868210 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in Carbohydrate Quality Index (CQI)
Number of subjects: 5373
Study 31868210 — intervention group
Group type: EXPERIMENTAL
Intervention: CQI quintile 5 compared to quintile 1
Number of subjects: 5373
Study 30948516 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral internal thoracic arteries (BITA)
Number of subjects: 3102
Study 30948516 — intervention group
Group type: COMPARATOR
Intervention: Single internal thoracic arteries (SITA)
Number of subjects: 3102
Study 29986562 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antibiotics (B group)
Number of subjects: 6
Study 29986562 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged antibiotics (C group)
Number of subjects: 6
Study 29986562 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (A group)
Number of subjects: 6
Study 29986562 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard antibiotics (E group)
Number of subjects: 6
Study 29986562 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged antibiotics (F group)
Number of subjects: 6
Study 29986562 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (D group)
Number of subjects: 6
Study 27470088 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain (500 mg/day)
Number of subjects: 40
Study 27470088 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (100 mg/day)
Number of subjects: 40
Study 24407913 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth Pursuit Training (SPT)
Number of subjects: 24
Study 24407913 — intervention group
Group type: COMPARATOR
Intervention: Visual Scanning Training (VST)
Number of subjects: 24
Study 22211833 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 units FFP
Number of subjects: 43
Study 22211833 — intervention group
Group type: COMPARATOR
Intervention: 2 units FFP plus 2 g fibrinogen concentrate
Number of subjects: 43
Study 20439791 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal and infancy home visits by nurses
Number of subjects: 613
Study 20439791 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 613
Study 18030102 — intervention group
Group type: EXPERIMENTAL
Intervention: Continence nurse intervention
Number of subjects: 51
Study 18030102 — intervention group
Group type: COMPARATOR
Intervention: Usual care by general practitioner
Number of subjects: 51
Study 16091379 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (1 mg/kg body weight) daily for 12 weeks
Number of subjects: 20
Study 16091379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12044433 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of protamine every 100 IU of heparin (Group A)
Number of subjects: 60
Study 12044433 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of protamine every 100 IU of heparin (Group B)
Number of subjects: 60
Study 12044433 — intervention group
Group type: COMPARATOR
Intervention: None (Group C)
Number of subjects: 60
Study 10460567 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml bupivacaine 0.125% with epinephrine 1/800 000 (group B)
Number of subjects: 20
Study 10460567 — intervention group
Group type: COMPARATOR
Intervention: 10 ml saline (group S)
Number of subjects: 20
Study 7637642 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 100 mg intramuscularly each month for 6 months
Number of subjects: 148
Study 7637642 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate treatment
Number of subjects: 148
Study 7637642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 148
Study 2576665 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg three times a day for 4 weeks
Number of subjects: 48
Study 2576665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once a day for 4 weeks
Number of subjects: 48
Study 2576665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31852672 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day prednisone (maintenance)
Number of subjects: 124
Study 31852672 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of 5 mg/day prednisone
Number of subjects: 124
Study 29955151 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI sertraline
Number of subjects: 184
Study 29955151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 28796934 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan for 6 months
Number of subjects: 124
Study 25134887 — intervention group
Group type: EXPERIMENTAL
Intervention: English only (EO) treatment
Number of subjects: 48
Study 25134887 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilingual skills in Spanish and English (BI) treatment
Number of subjects: 48
Study 25134887 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinguistic cognitive processing (NCP) treatment
Number of subjects: 48
Study 25134887 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish language skills
Number of subjects: 48
Study 22290266 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 receptor occupancy >77%
Number of subjects: 410
Study 22290266 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 receptor occupancy >80%
Number of subjects: 410
Study 22011387 — intervention group
Group type: EXPERIMENTAL
Intervention: IG1: invitation letter to participate in the screening
Number of subjects: 20994
Study 22011387 — intervention group
Group type: EXPERIMENTAL
Intervention: IG2: invitation letter and informative leaflet
Number of subjects: 20994
Study 22011387 — intervention group
Group type: EXPERIMENTAL
Intervention: IG3: invitation letter, informative leaflet and a phone call reminder
Number of subjects: 20994
Study 22011387 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20994
Study 18356336 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal night blindness
Number of subjects: 12829
Study 16971716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 712
Study 16971716 — intervention group
Group type: COMPARATOR
Intervention: Uncoated stents
Number of subjects: 712
Study 14508027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC) intervention for 15 weeks (three 45 minute classes per week)
Number of subjects: 36
Study 14508027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC) intervention
Number of subjects: 36
Study 14508027 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 36
Study 10720294 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) therapy
Number of subjects: 45
Study 8633944 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic high-dose aprotinin (group 1)
Number of subjects: 75
Study 8633944 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative low-dose aprotinin (group 2)
Number of subjects: 75
Study 8633944 — intervention group
Group type: COMPARATOR
Intervention: Nonmedicated control group (group 3)
Number of subjects: 75
Study 1444728 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (300 mg/d)
Number of subjects: 93
Study 1444728 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (150 mg/d)
Number of subjects: 93
Study 1444728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 6534186 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental support contracting
Number of subjects: 88
Study 6534186 — intervention group
Group type: COMPARATOR
Intervention: Routine, eclectic, 28-d inpatient alcoholism treatment program
Number of subjects: 88
Study 31607468 — intervention group
Group type: COMPARATOR
Intervention: WHO's recommended regimen (daily UNIMMAP containing 60 mg iron)
Number of subjects: 498
Study 31607468 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg screen-and-treat approach (daily UNIMMAP containing 60 mg iron for 7 days if weekly hepcidin was <2.5 μg/L)
Number of subjects: 498
Study 31607468 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg screen-and-treat approach (daily UNIMMAP containing 30 mg iron for 7 days if weekly hepcidin was <2.5 μg/L)
Number of subjects: 498
Study 31607468 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg screen-and-treat approach
Number of subjects: 498
Study 31607468 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg screen-and-treat approach
Number of subjects: 498
Study 28292572 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS)
Number of subjects: 102
Study 28292572 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 102
Study 26289604 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred intensity exercise intervention
Number of subjects: 26
Study 24927595 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic resource scarcity
Number of subjects: 0
Study 24927595 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual representations of African American faces under scarcity
Number of subjects: 0
Study 24927595 — intervention group
Group type: EXPERIMENTAL
Intervention: Face representations produced under scarcity
Number of subjects: 0
Study 24927595 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 22013152 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 533
Study 22013152 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 533
Study 20642296 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus acidophilus DDS‐1, Bifidobacterium lactis UABLA‐12 with fructo‐oligosaccharide at a dosage of 5 billion colony‐forming units twice daily for 8 weeks)
Number of subjects: 90
Study 20642296 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 90
Study 20642296 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 90
Study 18500527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic MR imaging at 3.0 T
Number of subjects: 10
Study 18500527 — intervention group
Group type: COMPARATOR
Intervention: Dynamic MR imaging at 1.5 T
Number of subjects: 10
Study 15986013 — intervention group
Group type: EXPERIMENTAL
Intervention: New immunosuppressive agents
Number of subjects: 0
Study 15986013 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern immunosuppression strategies
Number of subjects: 0
Study 15986013 — intervention group
Group type: EXPERIMENTAL
Intervention: Various combination protocols
Number of subjects: 0
Study 11886964 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 103
Study 11886964 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 103
Study 10461056 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic CHPP
Number of subjects: 32
Study 10461056 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic CHPP
Number of subjects: 32
Study 7780071 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 2.5 microgram/kg/min for 40 minutes (hydrated group)
Number of subjects: 10
Study 7780071 — intervention group
Group type: COMPARATOR
Intervention: Dopamine infusion at 2.5 microgram/kg/min for 40 minutes (nonhydrated group)
Number of subjects: 10
Study 2310656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim (15 micrograms kg‐1)
Number of subjects: 11
Study 2310656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 490882 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care (SC)
Number of subjects: 10940
Study 490882 — intervention group
Group type: COMPARATOR
Intervention: Referred Care (RC)
Number of subjects: 10940
Study 31566320 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchid drug-coated balloon (DCB)
Number of subjects: 74
Study 31566320 — intervention group
Group type: COMPARATOR
Intervention: PTA (standard percutaneous transluminal angioplasty)
Number of subjects: 74
Study 28339546 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRM-PVI
Number of subjects: 625
Study 28339546 — intervention group
Group type: COMPARATOR
Intervention: PVI-controls
Number of subjects: 625
Study 25227499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 441
Study 25227499 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab 1.25 mg
Number of subjects: 441
Study 23326457 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 405
Study 23326457 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 405
Study 23326457 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel biomarkers (Copeptin, MR-proADM, MR-proANP)
Number of subjects: 405
Study 21915733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 0.5 g
Number of subjects: 12
Study 21915733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 1.0 g
Number of subjects: 12
Study 21915733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 2.0 g
Number of subjects: 12
Study 21915733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan disodium (all doses)
Number of subjects: 12
Study 21915733 — intervention group
Group type: COMPARATOR
Intervention: Comparison of R-CTT and S-CTT
Number of subjects: 12
Study 18324419 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal vaccine (PV) in group 1 (nephrotic children on high-dose prednisone)
Number of subjects: 30
Study 18324419 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal vaccine (PV) in group 2 (patients in remission)
Number of subjects: 30
Study 18324419 — intervention group
Group type: COMPARATOR
Intervention: No vaccination in group 3 (control group)
Number of subjects: 30
Study 16224150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fas-positive cases
Number of subjects: 110
Study 16224150 — intervention group
Group type: COMPARATOR
Intervention: Fas-negative cases
Number of subjects: 110
Study 16224150 — intervention group
Group type: EXPERIMENTAL
Intervention: NSCLC patients
Number of subjects: 110
Study 16224150 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 and bcl-2 overexpressions
Number of subjects: 110
Study 12384635 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (Integrilin™, COR)
Number of subjects: 0
Study 12384635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10545309 — intervention group
Group type: COMPARATOR
Intervention: beta-blocker therapy (atenolol or metoprolol)
Number of subjects: 20
Study 10545309 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 20
Study 10545309 — intervention group
Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 20
Study 8669218 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methylnaltrexone IV at the end of surgery
Number of subjects: 120
Study 2180344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 27
Study 2180344 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 27
Study 2180344 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 27
Study 500844 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up method
Number of subjects: 0
Study 500844 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail follow-up method
Number of subjects: 0
Study 500844 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interview method
Number of subjects: 0
Study 500844 — intervention group
Group type: COMPARATOR
Intervention: All methods
Number of subjects: 0
Study 31185027 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted model for 60-s measure
Number of subjects: 1735
Study 31185027 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-fit model with covariates (age, sex, years of schooling, time of day)
Number of subjects: 1735
Study 31185027 — intervention group
Group type: EXPERIMENTAL
Intervention: First quartile of word generation
Number of subjects: 1735
Study 31185027 — intervention group
Group type: EXPERIMENTAL
Intervention: Second quartile of word generation
Number of subjects: 1735
Study 31185027 — intervention group
Group type: EXPERIMENTAL
Intervention: Third quartile of word generation
Number of subjects: 1735
Study 31185027 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth quartile of word generation
Number of subjects: 1735
Study 31185027 — intervention group
Group type: EXPERIMENTAL
Intervention: Average production starting point (intercept)
Number of subjects: 1735
Study 31185027 — intervention group
Group type: EXPERIMENTAL
Intervention: Production decay (slope)
Number of subjects: 1735
Study 28966188 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital impressions using intraoral optical scanning (IOS)
Number of subjects: 50
Study 28966188 — intervention group
Group type: COMPARATOR
Intervention: Conventional impressions
Number of subjects: 50
Study 28966188 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital impressions using IOS
Number of subjects: 50
Study 26010066 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent trajectories based on animacy cues (frog-like and jumping-like trajectories)
Number of subjects: 0
Study 26010066 — intervention group
Group type: COMPARATOR
Intervention: Incongruent trajectories not based on animacy cues (bouncing and rotating)
Number of subjects: 0
Study 26010066 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of speed ratio between movements
Number of subjects: 0
Study 26010066 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of temporal delay between movements
Number of subjects: 0
Study 23180157 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV6/11/16/18 vaccine
Number of subjects: 1749
Study 23180157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1749
Study 23180157 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated reference cohort
Number of subjects: 1749
Study 22333107 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 119
Study 22333107 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric air therapy (Control)
Number of subjects: 119
Study 19617208 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G‐CSF) at a dosage of 1 microg/kg/day starting on the sixth day after ovulation.
Number of subjects: 68
Study 19617208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 19617208 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G‐CSF)
Number of subjects: 68
Study 18085968 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese Internet Addiction Inventory (CIAI)
Number of subjects: 1029
Study 15128683 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (PIMs) prescribed to seniors
Number of subjects: 889
Study 15128683 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting benzodiazepines prescribed for longer than 30 days
Number of subjects: 889
Study 15128683 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin prescriptions
Number of subjects: 889
Study 15128683 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender of patients (women)
Number of subjects: 889